Skip to content

Are You Prepared For Questions About Medical Cannabis?

Are You Prepared For Questions About Medical Cannabis?

With over 85% of Americans supporting legalizing medical cannabis, it’s inevitable that patients will begin asking their primary care doctors about its use and overall efficacy. Doctors and other medical professionals will be called upon to be ‘sense-makers’ for a treatment they never studied in medical school and have limited available research to draw upon.  It’s a very challenging problem made more complex by the fact that medical cannabis use in individuals 65 and older increased 75% in the last 4 years, leaving many to wonder if there are any negative effects resulting from interactions with other medications. 

We at Arfinn Med understand the complexity of this issue and have released an updated version of our software to address this gap.  In addition to our EMR, completely online patient intake process, and telehealth solutions, we now have the ability to track patient outcomes dynamically through SMS updates, a customizable patient portal, and data fields specifically for cannabis patients.  This information will help medical professionals assist their patients throughout the whole process including efficacy review data on dispensaries and product type.     

We will also allow medical professionals with split practices to embed our platform in their existing EMR software so they can query our database of deidentified efficacy data for any patient demographic or condition. This will allow our users to confidently recommend cannabis to their patients with actual point-of-care analytics while keeping cannabis patients separate from the general patient population.  This will ensure cannabis patients will receive the proper follow-up and monitoring. 

If you’re looking for easy to use practice management software and a robust EMR, please reach out to us at info@arfinnmed.com to learn how we put the power of data into your patient care.      

Stories you may be interested in

Cannabis and Seniors

As more and more research comes out regarding the medical benefits of cannabis, it’s important to keep up with new research as it becomes available.  Here at Arfinn Med, we constantly review new studies and look at our own deidentified efficacy data to try to find any additional insights we can relay to our registered…
Read More

States with medical marijuana laws saw 20 percent drop in some opioid prescriptions

States with active medical marijuana laws saw certain opioid prescription rates drop nearly 20 percent compared to states without medical marijuana programs, according to a first-of-its-kind study out of Columbia University’s Irving Medical Center. Authors said the findings underscore the importance of providing patients with pain management alternatives, such as cannabis, in efforts to reduce…
Read More

Cannabis for Treating IBD: Hope or Hype?

Nausea, abdominal pain and changes in appetite. These are all things that can significantly impact one’s wellbeing if left untreated, yet they have all shown marked improvements when associated with cannabis. Yet, less is known about the effects of cannabis on inflammatory bowel disease, or IBD, a chronic inflammatory condition that impacts the gastrointestinal tract…
Read More

Customize Your Patient Notes with Arfinn Med

Joining the text messaging update, the Arfinn Med portal now presents the ability to create note taking templates. This innovative addition will allow physicians to streamline the data and information that they are collecting from patients, resulting in their cases staying aligned and concise. Additionally, through this function, physicians will be able to pick and…
Read More

Medical marijuana users tell their stories to Medical Cannabis Study Commission

Thursday, the Medical Cannabis Study Commission held its third meeting. The Commission has been tasked with presenting a policy recommendation to the legislature on exactly what the best medical marijuana bill should look like. The Commission held a public hearing in which a number of medical marijuana users claimed that the drug has benefitted them.…
Read More

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More

Leave a Comment

You must be logged in to post a comment.